Biopharmaceutical Firm Candel Therapeutics Prices Downsized US$72 Million IPO

Late clinical stage biopharmaceutical company Candel Therapeutics Inc. (Nasdaq: CADL) started publicly trading on the Nasdaq Global Market today under the symbol “CADL”. The firm’s initial public offering is looking to raise US$72.0 million and is expected to close on July 29, 2021.

The offering will be conducted through the issuance of 9,000,000 common shares selling at US$8.00 per share. This is an adjustment from the company’s original plan to issue 6.1 million shares with share price expectations between US$13.00 and US$15.00.

The company granted a 30-day over-allotment option to purchase additional 1,350,000 common shares at the same IPO price, potentially bringing proceeds up to US$82.8 million. Jefferies, Credit Suisse, BMO Capital Markets, and UBS Investment Bank are all acting as joint bookrunners for the said offering.

The Massachusetts-based biotech firm is in the business of developing novel oncolytic viral immunotherapies to treat patients with cancer, inducing “immunogenic cell death in cancer cells at the site of injection”. Currently, Candel Therapeutics has immunotherapy platforms in its portfolio –the lead adenovirus platform product candidate CAN-2409 and the lead HSV platform product candidate CAN-3310.


Information for this briefing was found via Sedar and Candel Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Investment Management Software Enfusion Prices US$318.75 Million IPO

Accounts payable automation software Enfusion, Inc. (NYSE: ENFN) started publicly trading on the New York...

Thursday, October 21, 2021, 02:19:00 PM

Biotech Firm PepGen Prices US$108 Million IPO

Biopharmaceutical company PepGen, Inc. (Nasdaq: PEPG) began trading on the Nasdaq Global Select Market on...

Monday, May 9, 2022, 02:27:00 PM

DWAC CEO-Advised Telco SPAC Nubia Brand International Prices US$110 Million IPO

Special purpose acquisition company Nubia Brand International Corp. (Nasdaq: NUBIU) started trading its securities on...

Friday, March 11, 2022, 02:20:00 PM

Foodservice SPAC Banyan Acquisition Aims To Conduct A US$210 Million IPO

Blank check company Banyan Acquisition Corporation (NYSE: BYN.U) is looking to raise US$210 million for...

Thursday, January 20, 2022, 02:24:00 PM

Video Surveillance Firm Maris-Tech Prices US$15.5 Million Nasdaq IPO

Video transmission technology provider Maris-Tech Ltd. (Nasdaq: MTEK) started trading on the Nasdaq Capital Market...

Wednesday, February 2, 2022, 02:21:00 PM